3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Glioblastoma
4
Glioma
3
Multiple Myeloma
2
Lymphoma
2
Astrocytoma
2
Sarcoma
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Oligodendroglioma
1
Neoplasms, Plasma Cell
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lipodystrophy, Congenital Generalized
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia
1
Hodgkin Disease
1
Gliosarcoma
1
Carcinoma
1
Advanced Fallopian Tube Carcinoma
1
Interventions
Cyclophosphamide
115
Dexamethasone
70
fludarabine phosphate
57
Cytarabine
56
fludarabine
52
Rituximab
51
Peripheral Blood Stem Cell Transplantation
40
Etoposide
40
Gemcitabine
39
Lenalidomide
38
pembrolizumab
33
Radiotherapy
33
Busulfan
33
Filgrastim
32
Carboplatin
31
Methotrexate
30
Cyclosporine
29
Cisplatin
29
Bortezomib
29
Mycophenolic Acid
28
Melphalan
28
venetoclax
27
Paclitaxel
26
Whole-Body Irradiation
24
Antilymphocyte Serum
23
Temozolomide
22
Granulocyte Colony-Stimulating Factor
20
Calcium Dobesilate
20
Bevacizumab
20
Tacrolimus
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Recurrence
×
Tetanus Toxoid
×
Clear all
NCT03615404
2021-01-28
ATTAC-P
Duke University
Phase 1
Completed
11 enrolled
7 charts